Lacklustre Performance Is Driving Immunocore Holdings Plc's (NASDAQ:IMCR) 31% Price Drop

Unfortunately for some shareholders, the Immunocore Holdings plc (NASDAQ:IMCR) share price has dived 31% in the last thirty days, prolonging recent pain. Instead of being rewarded, shareholders who

Simply Wall StJun 18 14:53 ET

Express News | Immunocore Announces Randomization Of The First Patient In The PRISM-MEL-301 Trial Of Brenetafusp (IMC-F106C; PRAME-A02), In Combination With Nivolumab, In First-line Advanced Or Metastatic Cutaneous Melanoma

BenzingaJun 18 07:13 ET

Express News | Immunocore Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

ReutersJun 18 07:00 ET

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n

Simply Wall StJun 15 09:24 ET

H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100

H.C. Wainwright analyst Patrick Trucchio maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 28.9% a

moomoo NewsJun 5 11:32 ET

A Quick Look at Today's Ratings for Immunocore(IMCR.US), With a Forecast Between $81 to $92

On Jun 04, major Wall Street analysts update their ratings for $Immunocore(IMCR.US)$, with price targets ranging from $81 to $92.Goldman Sachs analyst Rajan Sharma maintains with a buy rating.Barclays

moomoo NewsJun 4 09:00 ET